3,721 reports of this reaction
3.0% of all OCRELIZUMAB reports
#3 most reported adverse reaction
URINARY TRACT INFECTION is the #3 most commonly reported adverse reaction for OCRELIZUMAB, manufactured by Genentech, Inc.. There are 3,721 FDA adverse event reports linking OCRELIZUMAB to URINARY TRACT INFECTION. This represents approximately 3.0% of all 123,105 adverse event reports for this drug.
OCRELIZUMAB has an overall safety score of 78 out of 100. Patients taking OCRELIZUMAB who experience urinary tract infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
URINARY TRACT INFECTION is a less commonly reported adverse event for OCRELIZUMAB, but still significant enough to appear in the safety profile.
In addition to urinary tract infection, the following adverse reactions have been reported for OCRELIZUMAB:
The following drugs have also been linked to urinary tract infection in FDA adverse event reports:
URINARY TRACT INFECTION has been reported as an adverse event in 3,721 FDA reports for OCRELIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
URINARY TRACT INFECTION accounts for approximately 3.0% of all adverse event reports for OCRELIZUMAB, making it one of the most commonly reported side effect.
If you experience urinary tract infection while taking OCRELIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.